Skip to main content

CORRECTION article

Front. Oncol., 07 September 2021
Sec. Gynecological Oncology
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.742374
This article is part of the Research Topic Tumor Microenvironment and Therapeutic Resistance in Gynecologic Malignancies View all 13 articles

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

This article is a correction to:

  1. Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

    1. Read original article
Xuan Wei,,Xuan Wei1,2,3Juanjuan ShiJuanjuan Shi4Qianhan Lin,,Qianhan Lin1,2,3Xiaoxue Ma,,Xiaoxue Ma1,2,3Yingxin Pang,,Yingxin Pang1,2,3Hongluan Mao,,Hongluan Mao1,2,3Rui Li,,Rui Li1,2,3Wei Lu,,Wei Lu1,2,3Yu Wang,,*Yu Wang1,2,3*Peishu Liu,,*Peishu Liu1,2,3*
  • 1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China
  • 2Key Laboratory of Gynecology Oncology of Shandong Province, Qilu Hospital of Shandong University, Jinan, China
  • 3Shandong Engineering Laboratory for Urogynecology, Qilu Hospital of Shandong University, Jinan, China
  • 4Department of Gynecology and Obstetrics, Affiliated Tengzhou Center People’s Hospital of Jining Medical University, Tengzhou, China

A Corrigendum on
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

By Wei X, Shi J, Lin Q, Ma X, Pang Y, Mao H, Li R, Lu W, Wang Y and Liu P (2021). Front. Oncol. 11:642229. doi: 10.3389/fonc.2021.642229

In the original article, there was a mistake in Figure 5B as published. We recognized by ourself that the picture of “PI3K” was the same as that of “pan-AKT”, we made a mistake when we dragged the original figure into the AI software.

The corrected Figure 5B appears below.

FIGURE 5
www.frontiersin.org

Figure 5 ACLY knockdown inhibited PI3K/AKT pathway and activated AMPK pathway. (A) Western blotting was used to detect the differential expression of ACLY, PI3K/AKT pathway and p-AMPK-a in A2780 and A2780/CDDP cells. (B) Western blotting on A2780/CDDP-NC and A2780/CDDP-shACLY cells, and them under 20μM cisplatin treatment for 48 h, the bands were quantified and analyzed. The bands were quantitated with Image J software, statistical analysis was performed using Student’s t-test. (C) ROS production of the aforementioned cells and them under treatment of 20μM cisplatin for 48 h, statistical analysis was performed using Student’s t-test. (D) Tumor xenograft formation of A2780/CDDP-NC and A2780/CDDP-shACLY cells with treatment of cisplatin, with each group containing five mice. The difference in tumor weights was compared using Student’s t-test. (E) Proliferation of A2780/CDDP cells in respond to different concentration (low-dose, 10–30μM) of SB-204990, the growth curves were analyzed using one-way ANOVA test. (F) 24, 48, and 72 h IC50 of A2780/CDDP cells under treatment of cisplatin combined with different concentration of SB-204990 (from 0 to 30μM), 24 h IC50 of which were 32.34 (26.71–40.60), 16.75 (15.24–18.43), 11.08 (9.736–12.55), 9.495 (7.759–11.38) μM, respectively; 48 h IC50 of which were 25.37 (23.86–27.00), 12.33 (10.74–14.13), 7.983 (7.487–8.499), 6.979 (6.749–7.215) μM; 72 h IC50 of which were 16.96 (14.89–19.34), 9.727 (9.294–10.18), 7.407 (7.083–7.741), 5.922 (5.601–6.246) μM, respectively. All cell experiments were repeated three times at least. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 for statistical analysis of the indicated groups.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ACLY, ovarian cancer, cisplatin resistance, PI3K-AKT pathway, AMPK-ROS pathway

Citation: Wei X, Shi J, Lin Q, Ma X, Pang Y, Mao H, Li R, Lu W, Wang Y and Liu P (2021) Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway. Front. Oncol. 11:742374. doi: 10.3389/fonc.2021.742374

Received: 16 July 2021; Accepted: 20 August 2021;
Published: 07 September 2021.

Edited and reviewed by:

Haifeng Qiu, Zhengzhou University, China

Copyright © 2021 Wei, Shi, Lin, Ma, Pang, Mao, Li, Lu, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Peishu Liu, peishuliu@126.com; Yu Wang, yuerjade@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.